Results 301 to 310 of about 100,010 (342)
Exploring Experimental and In Silico Approaches for Antibody-Drug Conjugates in Oncology Therapies. [PDF]
Pharmaceuticals (Basel)de Almeida VM +2 more
europepmc +1 more source
Advances in antibody-drug conjugates for urothelial carcinoma treatment. [PDF]
Cancer Biol MedWei J +7 more
europepmc +1 more source
Comparative efficacy of antibody-drug conjugates and chemotherapy for malignant tumors: a systematic review and meta-analysis. [PDF]
Front OncolGao X +6 more
europepmc +1 more source
Characterisation of mAb104 Antibody-Drug Conjugates Targeting a Tumour-Selective HER2 Epitope. [PDF]
Cancers (Basel)Parakh S +10 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Biotechnology Letters, 2016
Antibody drug conjugates (ADCs) have emerged as a viable option in targeted delivery of highly potent cytotoxic drugs in treatment of solid tumors. At the time of writing, only two ADCs have received regulatory approval with >40 others in clinical development. The first generation ADCs suffered from a lack of specificity in amino acid site-conjugations,
openaire +3 more sources
Antibody drug conjugates (ADCs) have emerged as a viable option in targeted delivery of highly potent cytotoxic drugs in treatment of solid tumors. At the time of writing, only two ADCs have received regulatory approval with >40 others in clinical development. The first generation ADCs suffered from a lack of specificity in amino acid site-conjugations,
openaire +3 more sources
Current Opinion in Oncology, 2014
Antibody conjugates are a diverse complex class of therapeutics, consisting of a potent cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells or an extracellular target, that are having impact in the clinic.
openaire +2 more sources
Antibody conjugates are a diverse complex class of therapeutics, consisting of a potent cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells or an extracellular target, that are having impact in the clinic.
openaire +2 more sources
Toxicities From Antibody-Drug Conjugates
The Cancer Journal, 2022Abstract Antibody-drug conjugates are becoming increasingly important in the treatment of many cancer types. The 3 main structural components—antibody, linker, and payload—each contribute to the toxicity profiles of these drugs. In addition to cytopenias and gastrointestinal adverse effects attributed to the chemotherapy payloads, each drug ...
Andrew C, Johns, Matthew T, Campbell
openaire +2 more sources
Antibody–Drug Conjugate Payloads
2013Toxin payloads, or drugs, are the crucial components of therapeutic antibody-drug conjugates (ADCs). This review will give an introduction on the requirements that make a toxic compound suitable to be used in an antitumoral ADC and will summarize the structural and mechanistic features of four drug families that yielded promising results in preclinical
Jan, Anderl +3 more
openaire +2 more sources